Prix Frontage Holdings Corp (01521.HK)

Frontage Holdings Corp. engages in the provision of research and analytical and development services throughout the drug discovery and development process. The company is headquartered in Exton, Pennsylvania and currently employs 1,540 full-time employees. The company went IPO on 2019-05-30. The company provides laboratory and related services to pharmaceutical and agrochemical companies, as well as bioequivalence clinical and chemical services. The firm has two main divisions: Global Laboratory Services and Global Drug Discovery & Development Services. The Global Laboratory Services division offers laboratory testing support for clients involved in drug development. The Global Drug Discovery & Development Services division includes Drug Development Unit, the Drug Discovery Unit, and the Pharmaceutical Product Development Unit. Its Global Laboratory Services encompass regulated and non-regulated bioanalysis (both small and large molecules), biomarkers, genomics, manufacturing and controls analytical testing, and central laboratory services. The Drug Development Unit includes drug metabolism and pharmacokinetics, Safety and Toxicology. The firm's segments include North America and Europe and PRC.